Canada's Jamieson Wellness Q2 revenue beats; set to be acquired by Kirin Holdings
Canada's Jamieson Wellness Q2 revenue beats; set to be acquired by Kirin Holdings
Overview
Canada vitamins and supplements maker's Q2 revenue rose 17%, beating analyst expectations
Adjusted diluted EPS for Q2 beat analyst expectations
Company to be acquired by Kirin Holdings; withdraws 2026 guidance due to pending deal
Outlook
Jamieson Wellness withdraws fiscal 2026 financial guidance due to pending acquisition by Kirin Holdings
Company cites uncertainty around transaction timing and integration costs for guidance withdrawal
Result Drivers
CHINA PROMOTIONS - Co said successful 6/18 campaign and digital platform growth drove revenue gains in China
PRODUCT INNOVATION - Co cited new products, especially in sleep and stress categories, as supporting growth in Canada
DIGITAL COMMERCE - Co said digital commerce and flagship programs at key retailers fueled U.S. revenue growth
Company press release: ID:nCNWnldCwa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | C$233.84 mln | C$223.03 mln (4 Analysts) |
Q2 Adjusted EPS | Beat | C$0.46 | C$0.41 (4 Analysts) |
Q2 Adjusted Net Income |
| C$19.92 mln |
|
Q2 Adjusted EBITDA |
| C$39.43 mln |
|
Q2 Gross Margin |
| 41.6% |
|
Q2 Gross Profit |
| C$97.39 mln |
|
Q2 Operating Margin |
| 12.7% |
|
Q2 Pretax Profit |
| C$25.45 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the food processing peer group is "buy"
Wall Street's median 12-month price target for Jamieson Wellness Inc. is C$45.00, about 8.4% above its August 5 closing price of C$41.50
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
Aug 5 - Herbalife Q2 adjusted EPS misses estimates on FX headwinds
Aug 4 - USANA Health Sciences Q2 sales fall amid weaker Hiya and Rise performance
Aug 6 - Glanbia hikes profit forecast as weight-loss drugs boost demand for protein products
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Jamieson Wellness
See all newsAs weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Brief: Jamieson Wellness - Receives Final Court Approval For Plan Of Arrangement
Canada Research Roundup: American Tungsten, Isoenergy, Wellstar Technologies
Brief: Jamieson Wellness Inc Obtains Shareholder Approval For Sale To Kirin Holdings Company, Limited
Brief: Jamieson Wellness Says ISS & Glass Lewis Recommend Shareholders Vote For Kirin Deal At C$45.75 Per Share